This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xuan, J.-A. Articles by Parry, G. Search for Related Content PubMed PubMed Citation Articles by Xuan, J.-A. Articles by Parry, G.

Antibodies Neutralizing Hepsin Protease Activity Do Not Impact Cell Growth but Inhibit Invasion of Prostate and Ovarian Tumor Cells in Culture

Departments of ¹ Cancer Research, ² Systems Biology, ³ Pharmacology, and ⁴ Chemistry, Berlex Biosciences, Richmond, California

Requests for reprints: Gordon Parry, Department of Cancer Research, Berlex Biosciences, 2600 Hilltop Drive, Richmond, CA 94806. Phone: 510-669-4755; Fax: 510-669-4270; E-mail: gordon_parry{at}berlex.com.

Hepsin is a type II transmembrane serine protease that is expressed in normal liver, and at lower levels in kidney, pancreas, and testis. Several studies have shown that hepsin mRNA is significantly elevated in most prostate tumors, as well as a significant fraction of ovarian and renal cell carcinomas and hepatomas. Although the overexpression of mRNA in these tumors has been extensively documented, there has been conflicting literature on whether hepsin plays a role in tumor cell growth and progression. Early literature implied a role for hepsin in human tumor cell proliferation, whereas recent studies with a transgenic mouse model for prostate cancer support a role for hepsin in tumor progression and metastases. To evaluate this issue further, we have expressed an activatable form of hepsin, and have generated a set of monoclonal antibodies that neutralize enzyme activity. The neutralizing antibodies inhibit hepsin enzymatic activity in biochemical and cell-based assays. Selected neutralizing and nonneutralizing antibodies were used in cell-based assays with tumor cells to evaluate the effect of antibodies on tumor cell growth and invasion. Neutralizing antibodies failed to inhibit the growth of prostate, ovarian, and hepatoma cell lines in culture. However, potent inhibitory effects of the antibodies were seen on invasion of ovarian and prostate cells in transwell-based invasion assays. These results support a role for hepsin in tumor cell progression but not in primary tumor growth. Consistent with this, immunohistochemical experiments with a mouse monoclonal antibody reveal progressively increased staining of prostate tumors with advanced disease, and in particular, extensive staining of bone metastatic lesions. (Cancer Res 2006; 66(7): 3611-9)

This article has been cited by other articles:

				W. Li, B.-E. Wang, P. Moran, T. Lipari, R. Ganesan, R. Corpuz, M. J.C. Ludlam, A. Gogineni, H. Koeppen, S. Bunting, et al. Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis Cancer Res., November 1, 2009; 69(21): 8395 - 8402. [Abstract] [Full Text] [PDF]

				M. Tripathi, S. Nandana, H. Yamashita, R. Ganesan, D. Kirchhofer, and V. Quaranta Laminin-332 Is a Substrate for Hepsin, a Protease Associated with Prostate Cancer Progression J. Biol. Chem., November 7, 2008; 283(45): 30576 - 30584. [Abstract] [Full Text] [PDF]

				Y. Wu, C. Eigenbrot, W.-C. Liang, S. Stawicki, S. Shia, B. Fan, R. Ganesan, M. T. Lipari, and D. Kirchhofer Structural insight into distinct mechanisms of protease inhibition by antibodies PNAS, December 11, 2007; 104(50): 19784 - 19789. [Abstract] [Full Text] [PDF]

				P. Moran, W. Li, B. Fan, R. Vij, C. Eigenbrot, and D. Kirchhofer Pro-urokinase-type Plasminogen Activator Is a Substrate for Hepsin J. Biol. Chem., October 13, 2006; 281(41): 30439 - 30446. [Abstract] [Full Text] [PDF]